Inventiva S.A. (NASDAQ:IVA) Receives Consensus Rating of "Moderate Buy" from Brokerages

Inventiva S.A. (NASDAQ:IVA - Get Free Report) has been given a consensus rating of "Moderate Buy" by the five ratings firms that are covering the firm, Marketbeat Ratings reports. One analyst has rated the stock with a hold recommendation and four have assigned a buy recommendation to the company. The average 1-year price objective among analysts that have issued ratings on the stock in the last year is $10.40.

Several research analysts have recently commented on the company. HC Wainwright reiterated a "buy" rating and issued a $13.00 price objective on shares of Inventiva in a report on Friday, March 28th. Guggenheim decreased their price target on Inventiva from $12.00 to $9.00 and set a "buy" rating on the stock in a research note on Friday, April 4th. Finally, TD Cowen began coverage on Inventiva in a research report on Friday, February 21st. They issued a "buy" rating and a $10.00 price objective for the company.

Inventiva Price Performance

NASDAQ:IVA traded up $0.08 during trading hours on Friday, reaching $3.12. The company's stock had a trading volume of 11,131 shares, compared to its average volume of 62,306. The firm has a 50-day simple moving average of $2.82 and a 200-day simple moving average of $2.53. Inventiva has a 1 year low of $1.53 and a 1 year high of $3.98.

Inventiva Company Profile

Inventiva SA, a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH) and other diseases. Its lead product candidate is Lanifibranor, which is in Phase III clinical trial to treat NASH. The company also develops Odiparcil for the treatment of patients with mucopolysaccharidoses type VI.